Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in NSCLC with MET Deregulation
NCT03911193Phase 2Unknown
- Sponsor
- Fondazione Ricerca Traslazionale
- Start
- Sep 2018
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cabozantinib in non-small cell lung cancer (NSCLC), sponsored by Fondazione Ricerca Traslazionale. Status: unknown.
02
Drugs
cabozantinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03911193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03911193.